Ekso Bionics Stock Price, News & Analysis

Ekso Bionics (Nasdaq: EKSO) reported Q3 2025 results on Oct 28, 2025: revenue $4.2M (up 2% YoY, up 105% sequentially), gross margin 60.3% (up 680 bps YoY, driven by higher Enterprise Health sales and lower device cost), and net loss $1.4M (improved 31% YoY, $0.54 per share). Operating expenses declined across S&M, R&D and G&A mainly due to Employee Retention Credit benefits.

The company had $2.7M cash at Sept 30, 2025 and announced it is exploring strategic transactions, which may include divestiture or acquisition and could require substantial issuance of company securities.

Ekso Bionics (NASDAQ: EKSO), a leader in exoskeleton technology, reported its Q2 2025 financial results, showing significant challenges. Revenue declined to $2.1 million from $5.0 million in Q2 2024, primarily due to lower Enterprise Health device sales. The company posted a net loss of $2.7 million, or $1.24 per share.

Despite challenges, Personal Health products grew over 50% year-over-year in H1 2025. Notable developments include naming Bionic P&O as first Ekso Indego Personal device distributor, joining NVIDIA Connect program for AI development, launching an AI voice agent for EksoNR, and introducing eksoUniversity for physical therapy education.

Gross margin decreased to 40% from 53% year-over-year, while cash position stood at $5.2 million as of June 30, 2025.

Ekso Bionics (NASDAQ:EKSO), a leader in medical and industrial exoskeleton technology, has scheduled its Q2 2025 financial results release for July 28, 2025 after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss financial performance and recent business developments.

Investors can join via phone by dialing 877-407-6184 (domestic) or 201-389-0877 (international). The presentation will also be available through a live webcast and archived on the company's investor relations website.

Ekso Bionics (Nasdaq: EKSO) has launched eksoUniversity, a new online continuing education platform for physical therapists (PTs) and physical therapy assistants (PTAs). The platform offers on-demand courses approved for CEUs in over 30 states, specifically targeting professionals working with neurological conditions.

CEO Scott Davis emphasized that while the platform is expected to generate incremental revenue, its primary value lies in educating the neurological physical therapy community about various treatment options. The courses help healthcare professionals maintain their licensing requirements while staying current with evolving treatment methods and technologies.

Ekso Bionics (NASDAQ: EKSO) has demonstrated initial proof-of-concept for integrating AI capabilities into their medical and industrial exoskeleton devices, following their recent acceptance into the NVIDIA Connect Program. The company has developed an AI voice agent for their EksoNR device, implemented using NVIDIA Jetson Orin Nano hardware, NVIDIA JetPack SDK, and OpenAI tools. The Edge AI system can operate with or without cloud connectivity. Ekso Bionics leverages a substantial database of approximately 350,000 patient sessions and over 15 million step-by-step data points, growing by about 60,000 patient steps daily, positioning them uniquely to advance exoskeleton technology through AI integration.

Ekso Bionics (NASDAQ: EKSO) has announced a revised effective date for its previously approved 1-for-15 reverse stock split, now scheduled for June 2, 2025, at 12:01 a.m. Pacific time. The company's outstanding shares will decrease from approximately 35.5 million to 2.4 million shares post-split. This action follows a Nasdaq non-compliance notice received in December 2024 regarding the minimum bid price requirement. The reverse split aims to raise the stock's trading price to meet Nasdaq's $1.00 minimum bid requirement for at least ten consecutive trading days. The split will affect all issued shares, including adjustments to stock options, warrants, and RSUs, with fractional shares being rounded up to the next whole share.

Ekso Bionics (NASDAQ: EKSO) has announced a 1-for-15 reverse stock split effective May 27, 2025. The split will reduce outstanding common stock from approximately 35,289,695 to 2,352,646 shares. The primary purpose is to raise the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 for at least ten consecutive trading days.

The reverse split, approved by shareholders on May 16, 2025, will affect all issued shares, including adjustments to stock options, warrants, and restricted stock units. No fractional shares will be issued, with any fractional shares being rounded up. The company will maintain its "EKSO" trading symbol but will trade under a new CUSIP number 282644 400.

Ekso Bionics (NASDAQ: EKSO) has been accepted into the prestigious NVIDIA Connect program, marking a significant step in the company's AI development strategy. The exoskeleton technology leader plans to leverage NVIDIA's resources to develop the world's first foundation model for human motion in physical rehabilitation.

Through this selective program, Ekso Bionics will gain access to specialized training, priority engineering support, and exclusive NVIDIA GPU platforms and development kits. The company aims to integrate new AI capabilities across its Enterprise Health and Personal Health device portfolio. CEO Scott Davis emphasized that while their exoskeleton technology is already advanced, this collaboration represents just the beginning of their AI journey in rehabilitation technology.

Ekso Bionics (NASDAQ: EKSO) reported its Q1 2025 financial results, showing a revenue decline to $3.4 million from $3.8 million in Q1 2024. The company announced two strategic partnerships: naming National Seating & Mobility (NSM) as exclusive Ekso Indego Personal device distributor in the U.S. CRT industry, and Bionic Prosthetics & Orthotics Group as its first distributor in the orthotics and prosthetics sector. Gross margin improved to 53.5% from 51.9%. Net loss narrowed to $2.9 million ($0.12 per share) compared to $3.4 million ($0.20 per share) in Q1 2024. The company improved its operating cash burn by 43% and secured $3.8 million from warrant exercises, ending the quarter with $8.1 million in cash and restricted cash.